Núñez-Pereira, SusanaBenavent, EvaUlldemolins, MartaSobrino-Díaz, BeatrizIribarren, José AntonioEscudero-Sánchez, RosaToro, María Dolores delNodar, AndrésSorli Redó, M. LuisaBahamonde, AlbertoVilchez, Helem H.Gasch, OriolMuñez, ElenaRodríguez-Montserrat, DavidGarcía-País, María JoséHaddad, SleimanSellarès-Nadal, JuliaMurillo, OscarRodríguez-Pardo, DolorsGEIO–SEIMC2023-09-062023-09-062023Núñez-Pereira S, Benavent E, Ulldemolins M, Sobrino-Díaz B, Iribarren JA, Escudero-Sánchez R, Del Toro MD, Nodar A, Sorli L, Bahamonde A, Vilchez HH, Gasch O, Muñez E, Rodríguez-Montserrat D, García-País MJ, Haddad S, Sellarès-Nadal J, Murillo O, Rodríguez-Pardo D, GEIO–SEIMC. Cutibacterium spp. infections after instrumented spine surgery have a good prognosis regardless of rifampin use: a cross-sectional study. Antibiotics. 2023;12(3):518. DOI: 10.3390/antibiotics120305182079-6382http://hdl.handle.net/10230/57822Infection after spinal instrumentation (IASI) by Cutibacterium spp. is being more frequently reported. The aim of this study was to analyse the incidence, risk factors, clinical characteristics, and outcome of a Cutibacterium spp. IASI (CG) compared with non-Cutibacterium IASI (NCG) infections, with an additional focus on the role of rifampin in the treatment. All patients from a multicentre, retrospective, observational study with a confirmed IASI between January 2010 and December 2016 were divided into two groups: (CG and NCG) IASI. Baseline, medical, surgical, infection treatment, and follow-up data were compared for both groups. In total, 411 patients were included: 27 CG and 384 NCG. The CG patients were significantly younger. They had a longer median time to diagnosis (23 vs. 13 days) (p = 0.025), although 55.6% debuted within the first month after surgery. Cutibacterium patients were more likely to have the implant removed (29.6% vs. 12.8%; p = 0.014) and received shorter antibiotic regimens (p = 0.014). In 33% of Cutibacterium cases, rifampin was added to the baseline therapy. None of the 27 infections resulted in treatment failure during follow-up regardless of rifampin use. Cutibacterium spp. is associated with a younger age and may cause both early and late IASIs. In our experience, the use of rifampin to improve the outcome in the treatment of a Cutibacterium spp. IASI is not relevant since, in our series, none of the cases had therapeutic failure regardless of the use of rifampin.application/pdfeng© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).info:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/antibiotics12030518Cutibacterium spp.RifampinSpine surgerySurgical site infectioninfo:eu-repo/semantics/openAccess